secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120706
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health nominates RJVA-002 GIP/GLP-1 gene therapy; positive 13-week preclinical data on RJVA-001
--------------------------------------------------------------------------------

- Nominated RJVA-002 as first GIP/GLP-1 pancreatic gene therapy lead candidate for obesity.
- RJVA-001 shows sustained weight and blood sugar control at 13 weeks in DIO mice on high-fat diet.
- Over 10% of islet cells expressed GLP-1 after single dose; no safety signals.
- Data independently validated by Dr. Randy Seeley at University of Michigan.
- Fractyl plans to use durable efficacy results for RJVA-001 FIH data package.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/0000950170-24-120706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/guts-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer